Merck is pleased to announce that KEYTRUDA

Pfizer Oncology is proud to announce that the indications for IBRANCE

NCCN© has updated the Clinical Practice Guidelines

New combination now approved for CLL

Permanent J-codes for Genentech Hematology Products

Announcing a New First-Line Indication for a Genentech Therapy

New indication for VENCLEXTA® (venetoclax tablets)

XOSPATA Is the First FDA-Approved FLT3 Inhibitor Indicated for Patients with Relapsed or Refractory FLT3m+ Acute Myeloid Leukemia (AML)1

NEW PRODUCT ANNOUNCEMENT

FDA Approval of VIZIMPRO® (dacomitinib) tablets

Information About KISQALI® (ribociclib)

US FDA Approves New Treatment for Certain Hairy Cell Leukemia Patients

Announcing a new treatment option for your WM patients

Pfizer Filgrastim biosimilar approval

New MAC for NJ announced

Highmark is the new MAC for PA, NJ, DE, MD & DC.
Additional information

ASP Update on Aranesp

by Sandy Victor

If you use Aranesp, Medicare adjusted the ASP for all 3 previous quarters of 2007 as of October 1st.

Aloxi Documents

NPPES and the NPI Registry

Many of you have noted the recent instability of NPPES and the NPI Registry. CMS has begun implementing changes that should eliminate the instability. We expect that these changes will be completed next week.

New Diagnosis Codes

Important: There is NO GRACE period for the new Diagnosis codes. The New Diagnosis Codes are effective 10/01/2007.

FDA Approval of Vidaza NDA Supplement for IV Administration

Click Here

DMERC Oral Anti-cancer Drugs

United Healthcare/Oxford

Patients must use LabCorp Laboratories or a local hospital that is participating with the plans. DO NOT USE QUEST EFFECTIVE 01/01/2007.

Herceptin Coverage

Expanded Coverage of Bevacizumab (Avastin )

New FDA Approval for Gemzar in Ovarian Cancer

approval April 2006

Reimbursement Hotlines 2005

IMPORTANT

The information provided by NJSOM through our meetings or website is for educational purposes only. NJSOM is not responsible for implementation and or suggesting what should be done in your practice. All information provided should be reviewed and assessed by each individual practice.